Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› EGFR Activating Mutation
Clinical trial register · China

EGFR Activating Mutation Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 2 Wuhan 2 Beijing 2 Guangzhou 2 Changsha 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai2 Wuhan2 Beijing2 Guangzhou2 Changsha1
All 7 locations
Target enrolment
to

EGFR Activating Mutation trials in China

10 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT07897188EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3
425
Shanghai
2026-10-30
Recruiting
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
NCT07637448Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation, PD-1 Antibody
Nanfang Hospital, Southern Medical University
Phase 2
32
Guangzhou
2026-05-21
Recruiting
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NCT07348965NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
Guangzhou University of Traditional Chinese Medicine
Not applicable
42
Guangzhou
2026-03-01
Not yet open
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
NCT07287904Lung Cancer (NSCLC), EGFR Activating Mutation, Adenocarcinoma Lung, Postoperative Adjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Wuhan
2025-12-25
Not yet open
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
NCT07182708NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
62
Beijing
2025-10-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
32
Tianjin
2024-04-09
Recruiting
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Recruiting
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
TYK Medicines, Inc
Phase 3
680
Changsha, Shanghai
2022-06-08
By invitation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
500
Wuhan
2021-01-01
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/egfr-activating-mutation

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition EGFR Activating Mutation.

How many EGFR Activating Mutation trials are recruiting in China?

6 of the 10 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (EGFR Activating Mutation), 10 studies
PhaseStudiesRecruitingShare
Phase 24340%
Phase 33230%
Observational2020%
Not applicable1110%

Most active sponsors

Lead sponsors with the most studies (EGFR Activating Mutation)
Lead sponsorStudiesRecruiting
TYK Medicines, Inc22
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology20
Guangzhou University of Traditional Chinese Medicine11
Jiangsu Aosaikang Pharmaceutical Co., Ltd.10
Nanfang Hospital, Southern Medical University11
Peking University Cancer Hospital & Institute10
Sun Yat-sen University11
Tianjin Medical University Cancer Institute and Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.